DANAHER CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DANAHER CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.36B | Feb 21, 2019 |
| FY2018 | Sep 28, 2018 | $4.85B | Feb 21, 2019 |
| FY2018 | Jun 29, 2018 | $4.98B | Feb 21, 2019 |
| FY2018 | Mar 30, 2018 | $4.70B | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $5.09B | Feb 21, 2019 |
| FY2018 | Sep 29, 2017 | $4.53B | Feb 21, 2019 |
| FY2018 | Jun 30, 2017 | $4.51B | Feb 21, 2019 |
| FY2018 | Mar 31, 2017 | $4.21B | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $16.88B | Feb 21, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.57B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $23.88B | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | $6.41B | Feb 21, 2024 |
| FY2023 | Sep 29, 2023 | $5.62B | Feb 21, 2024 |
| FY2023 | Jun 30, 2023 | $5.91B | Feb 21, 2024 |
| FY2023 | Mar 31, 2023 | $5.95B | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | $7.13B | Feb 21, 2024 |
| FY2023 | Sep 30, 2022 | $6.46B | Feb 21, 2024 |
| FY2023 | Jul 1, 2022 | $6.53B | Feb 21, 2024 |
| FY2023 | Apr 1, 2022 | $6.53B | Feb 21, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.09B | Feb 21, 2018 |
| FY2017 | Sep 29, 2017 | $4.53B | Feb 21, 2018 |
| FY2017 | Jun 30, 2017 | $4.51B | Feb 21, 2018 |
| FY2017 | Mar 31, 2017 | $4.21B | Feb 21, 2018 |
| FY2017 | Dec 31, 2016 | $4.58B | Feb 21, 2018 |
| FY2017 | Sep 30, 2016 | $4.13B | Feb 21, 2018 |
| FY2017 | Jul 1, 2016 | $4.24B | Feb 21, 2018 |
| FY2017 | Apr 1, 2016 | $3.92B | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | $4.32B | Feb 22, 2017 |
| FY2016 | Oct 2, 2015 | $3.51B | Feb 22, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.52B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $14.21B | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | $3.78B | Feb 21, 2024 |
| FY2023 | Sep 29, 2023 | $3.28B | Feb 21, 2024 |
| FY2023 | Jun 30, 2023 | $3.32B | Feb 21, 2024 |
| FY2023 | Mar 31, 2023 | $3.66B | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | $4.23B | Feb 21, 2024 |
| FY2023 | Sep 30, 2022 | $3.89B | Feb 21, 2024 |
| FY2023 | Jul 1, 2022 | $4.01B | Feb 21, 2024 |
| FY2023 | Apr 1, 2022 | $4.06B | Feb 21, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.61B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.90B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $4.76B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $7.21B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $6.43B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $3.65B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $3.01B | Feb 23, 2022 |
| FY2018 | Dec 31, 2018 | $746.80M | Feb 21, 2019 |
| FY2018 | Sep 28, 2018 | $663.70M | Feb 21, 2019 |
| FY2018 | Jun 29, 2018 | $673.80M | Feb 21, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.69B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.86B | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | $1.34B | Feb 21, 2024 |
| FY2023 | Sep 29, 2023 | $1.19B | Feb 21, 2024 |
| FY2023 | Jun 30, 2023 | $1.16B | Feb 21, 2024 |
| FY2023 | Mar 31, 2023 | $1.52B | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | $2.00B | Feb 21, 2024 |
| FY2023 | Sep 30, 2022 | $1.72B | Feb 21, 2024 |
| FY2023 | Jul 1, 2022 | $1.89B | Feb 21, 2024 |
| FY2023 | Apr 1, 2022 | $1.93B | Feb 21, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.60B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.50B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.53B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.50B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.35B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $1.13B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $1.06B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $956.40M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $975.10M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.24B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $7.76B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.33B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $7.12B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $6.82B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.90B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $5.59B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $5.39B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $5.04B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $5.62B | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.42B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.69B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.16B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $8.52B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $8.36B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $6.21B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $3.95B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $4.02B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.48B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $3.52B | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.38B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.12B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.24B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $791.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $636.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $584.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $570.70M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $589.60M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.46B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $77.54B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $84.49B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $84.35B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $83.18B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $76.16B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $62.08B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $47.83B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $46.65B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $45.30B | Feb 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $8.44B | Feb 24, 2011 |
| FY2010 | Dec 31, 2009 | $7.97B | Feb 24, 2011 |
| FY2010 | Dec 31, 2008 | $7.68B | Feb 24, 2011 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.53B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $49.54B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $53.49B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $50.08B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $45.17B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $39.77B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $30.27B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $28.21B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $26.36B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $23.00B | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.15B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $40.50B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $41.61B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $37.28B | Feb 20, 2025 |
| FY2023 | Sep 30, 2022 | $35.85B | Feb 21, 2024 |
| FY2023 | Dec 31, 2021 | $38.68B | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $35.42B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $22.71B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $22.58B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $21.77B | Feb 21, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.89B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $44.19B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $41.07B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $39.21B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $32.83B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $27.16B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $24.17B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $25.16B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $22.81B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $20.70B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $19.91B | Feb 21, 2020 |
| FY2019 | Dec 31, 2018 | $787.80M | Feb 21, 2020 |
| FY2019 | Dec 31, 2017 | $630.30M | Feb 21, 2020 |
| FY2019 | Dec 31, 2016 | $963.70M | Feb 21, 2020 |
| FY2018 | Dec 31, 2015 | $790.80M | Feb 21, 2019 |
| FY2017 | Dec 31, 2014 | $3.01B | Feb 21, 2018 |
| FY2016 | Dec 31, 2013 | $3.12B | Feb 22, 2017 |
| FY2015 | Dec 31, 2012 | $1.68B | Feb 24, 2016 |
| FY2014 | Dec 31, 2011 | $537.00M | Feb 25, 2015 |
| FY2013 | Dec 31, 2010 | $1.63B | Feb 21, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.42B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $16.01B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $18.40B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $19.68B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $22.18B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $21.20B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $21.73B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $9.74B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $10.52B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $12.27B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Sep 29, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Mar 31, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | 3 | Feb 21, 2024 |
| FY2023 | Sep 30, 2022 | 2 | Feb 21, 2024 |
| FY2023 | Jul 1, 2022 | 2 | Feb 21, 2024 |
| FY2023 | Apr 1, 2022 | 2 | Feb 21, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Sep 29, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Jun 30, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Mar 31, 2023 | 1 | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | 2 | Feb 21, 2024 |
| FY2023 | Sep 30, 2022 | 2 | Feb 21, 2024 |
| FY2023 | Jul 1, 2022 | 2 | Feb 21, 2024 |
| FY2023 | Apr 1, 2022 | 2 | Feb 21, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 706.90M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 719.10M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 739.20M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 728.30M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 715.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 711.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 695.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 701.50M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 696.60M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 692.20M | Feb 21, 2018 |